Oryx Fund

Oryx Fund is an Abu Dhabi-based venture vehicle managed within the broader Hambro Perks platform, investing in early-stage technology companies with regional ties to the Middle East and selective international exposure. Healthcare interest centers on digital health and health IT, consistent with the firm’s broader software-led thesis. Limited public information is available on a dedicated healthcare partner or deep clinical specialization, and health deals appear to be evaluated within the firm’s general early-stage technology framework rather than through a vertical specialist team.

Check sizes are in the one to five million dollar range, with deployment at seed and Series A stages. The fund operates from Abu Dhabi with focus on the United Arab Emirates and broader MENA region, engaging with founders building regionally relevant healthcare technology businesses. Stage focus means Oryx is most useful as a first or second institutional investor rather than a growth-stage partner, with follow-on participation in subsequent rounds shaped by individual deal performance and fund sizing.

For founders, Oryx Fund is most relevant to digital health and health IT teams building for the GCC and broader MENA markets, where regional regulatory frameworks, payer dynamics, and consumer behavior differ meaningfully from US or European comparables. Founders should expect engagement that emphasizes regional commercial realism, ties into Abu Dhabi and UAE healthcare systems, and the broader Hambro Perks network and capabilities. Companies pitching biotech, therapeutics, or capital-intensive devices will not align with the technology-led thesis. Strong regional commercialization plans and credible regulatory pathways within the UAE and Saudi Arabia will resonate more than generic global market narratives.